In a neoadjuvant study with Ipilimumab in advanced melanoma, the treatment induced an expansion of activated CD4+ and CD8+ melanoma-specific T cell clones, an increase in circulating Treg, with greater Treg increase associated to improved PFS, and a reduction in all MDSC subsets, especially the M-MDSC fraction. The gene discussed is CD4; the disease is melanoma.